by Daniel Barker, Natural News:
Prostate cancer patients who receive hormone therapy as part of their treatment are twice as likely to develop Alzheimer’s and face an increased risk of depression, a pair of recent studies has shown.
A common treatment for prostate cancer involves the use of androgen-deprivation therapy (ADT) drugs, which reduce testosterone levels, which is required by prostate cancer cells so that they can grow and spread.
Two separate research projects focused on ADT drugs and discovered side effects other than those already associated with their use, such as weight gain, fatigue, reduced libido and sexual dysfunction.
The most recent of the two studies (both published in the Journal of Clinical Oncology), found a link between ADT and an elevated risk of depression among the nearly 45,000 men tested who had received the treatment.
Please follow SGT Report on Twitter & help share the message.